A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

ClinicalTrials.gov ID: NCT02336230

Public ClinicalTrials.gov record NCT02336230. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Study identification

NCT ID: NCT02336230
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Mesoblast, Inc.; Industry
Enrollment: 55 participants

Conditions and interventions

Conditions

Interventions

remestemcel-L Drug

Drug

Eligibility (public fields only)

Age range: 2 Months to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 3, 2015
Primary completion: Apr 8, 2018
Completion: Apr 8, 2018
Last update posted: Mar 16, 2022

2015 – 2018

United States locations

U.S. sites: 20
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
Children's Hospital Los Angeles	Los Angeles	California	90027	—
Children's Hospital of Orange County	Orange	California	92868	—
University of California at San Francisco	San Francisco	California	94143	—
Children's Hospital Colorado Center for Cancer/Blood Disorders	Aurora	Colorado	80045	—
Alfred I. DuPont Hospital for Children of the Nemours Foundation	Wilmington	Delaware	19803	—
Miami Children's Research Institute	Miami	Florida	33136	—
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	60611	—
Children's Hospital of Michigan	Detroit	Michigan	48201	—
University of Mississippi Medical Center	Jackson	Mississippi	39216	—
Washington University	St Louis	Missouri	63110	—
Columbia University Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10174	—
Albert Einstein College of Medicine	New York	New York	10467	—
Duke University Medical Center	Durham	North Carolina	27705	—
Oregon University	Portland	Oregon	97239	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Texas Transplant Institute	San Antonio	Texas	78229	—
Virginia Commonwealth University	Richmond	Virginia	23284	—
Fred Hutchinson Cancer Research	Seattle	Washington	98109	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02336230, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 16, 2022 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02336230 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →